Unknown

Dataset Information

0

Synthesis and bioactivity of readily hydrolysable novel cationic lipids for potential lung delivery application of mRNAs.


ABSTRACT: Lipid nanoparticles (LNPs) mediated mRNA delivery has gained prominence due to the success of mRNA vaccines against Covid-19, without which it would not have been possible. However, there is little clinical validation of this technology for other mRNA-based therapeutic approaches. Systemic administration of LNPs predominantly targets the liver, but delivery to other organs remains a challenge. Local approaches remain a viable option for some disease indications, such as Cystic Fibrosis, where aerosolized delivery to airway epithelium is the preferred route of administration. With this in mind, novel cationic lipids (L1-L4) have been designed, synthesized and co-formulated with a proprietary ionizable lipid. These LNPs were further nebulized, along with baseline control DOTAP-based LNP (DOTAP+), and tested in vitro for mRNA integrity and encapsulation efficiency, as well as transfection efficiency and cytotoxicity in cell cultures. Improved biodegradability and potentially superior elimination profiles of L1-L4, in part due to physicochemical characteristics of putative metabolites, are thought to be advantageous for prospective therapeutic lung delivery applications using these lipids.

SUBMITTER: Pei Y 

PROVIDER: S-EPMC9749011 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Synthesis and bioactivity of readily hydrolysable novel cationic lipids for potential lung delivery application of mRNAs.

Pei Yihua Y   Bao Yanjie Y   Sacchetti Cristiano C   Brady Juthamart J   Gillard Kyra K   Yu Hailong H   Roberts Scott S   Rajappan Kumar K   Tanis Steven P SP   Perez-Garcia Carlos G CG   Chivukula Padmanabh P   Karmali Priya P PP  

Chemistry and physics of lipids 20220203


Lipid nanoparticles (LNPs) mediated mRNA delivery has gained prominence due to the success of mRNA vaccines against Covid-19, without which it would not have been possible. However, there is little clinical validation of this technology for other mRNA-based therapeutic approaches. Systemic administration of LNPs predominantly targets the liver, but delivery to other organs remains a challenge. Local approaches remain a viable option for some disease indications, such as Cystic Fibrosis, where ae  ...[more]

Similar Datasets

| S-EPMC4285367 | biostudies-literature
| S-EPMC6825285 | biostudies-literature
| S-EPMC3129426 | biostudies-literature
| S-EPMC4100725 | biostudies-literature
| S-EPMC6023837 | biostudies-literature
| S-EPMC6336150 | biostudies-literature
| S-EPMC8154203 | biostudies-literature
| S-EPMC5571731 | biostudies-literature
| S-EPMC3156682 | biostudies-literature
| S-EPMC4051313 | biostudies-literature